Effects of intravenous apolipoprotein A-I/phosphatidylcholine discs on paraoxonase and platelet-activating factor acetylhydrolase in human plasma and tissue fluid
- PMID: 15306175
- DOI: 10.1016/j.atherosclerosis.2004.03.026
Effects of intravenous apolipoprotein A-I/phosphatidylcholine discs on paraoxonase and platelet-activating factor acetylhydrolase in human plasma and tissue fluid
Abstract
We have previously shown that intravenous apolipoprotein (apo) A-I/phosphatidylcholine (apo A-I/PC) discs increase plasma high-density lipoprotein (HDL) concentration in humans. We have now studied the associated changes in two enzymes, paraoxonase (PON) and platelet-activating factor acetylhydrolase (PAF-AH) that are carried in whole or in part by HDLs, and are thought to influence atherogenesis by hydrolyzing oxidized phospholipids in lipoproteins. Apo A-I/PC discs (40 mg/kg over 4 h) were infused into eight healthy males. Although plasma apo A-I and HDL cholesterol increased on average by 178 and 158%, respectively, plasma total PON and total PAF-AH concentrations did not rise. By the end of the infusion, HDL-associated PAF-AH had increased by 0.56 +/- 0.14 microg/mL (mean +/- S.D., P < 0.01), and nonHDL-associated PAF-AH had decreased by 0.84 +/- 0.11 microg/mL (P < 0.05). These changes were accompanied by an increase in the HDL-associated PAF-AH/apo A-I ratio from 0.19 to 0.35 (P < 0.05), and by a decrease in the nonHDL-associated PAF-AH/apo B ratio from 2.1 to 1.4 (P < 0.05). No changes in PON or PAF-AH concentrations were detected in prenodal lymph (tissue fluid), collected continuously from the leg. Our results show that the total concentrations of PON and PAF-AH in plasma are uninfluenced by plasma HDL concentration. PAF-AH transfers readily between HDLs and LDLs in vivo, and its distribution between them is determined partly by their relative concentrations and partly by HDL composition.
Similar articles
-
Effect of overexpression of human apo A-I in C57BL/6 and C57BL/6 apo E-deficient mice on 2 lipoprotein-associated enzymes, platelet-activating factor acetylhydrolase and paraoxonase. Comparison of adenovirus-mediated human apo A-I gene transfer and human apo A-I transgenesis.Arterioscler Thromb Vasc Biol. 2000 Oct;20(10):E68-75. doi: 10.1161/01.atv.20.10.e68. Arterioscler Thromb Vasc Biol. 2000. PMID: 11031226
-
Thyroid substitution therapy induces high-density lipoprotein-associated platelet-activating factor-acetylhydrolase in patients with subclinical hypothyroidism: a potential antiatherogenic effect.Thyroid. 2005 May;15(5):455-60. doi: 10.1089/thy.2005.15.455. Thyroid. 2005. PMID: 15929667 Clinical Trial.
-
Altered distribution of plasma PAF-AH between HDLs and other lipoproteins in hyperlipidemia and diabetes mellitus.J Lipid Res. 2003 Oct;44(10):2006-14. doi: 10.1194/jlr.D300021-JLR200. Epub 2003 Jul 16. J Lipid Res. 2003. PMID: 12867534
-
Effect of hypolipidemic drugs on lipoprotein-associated platelet activating factor acetylhydrolase. Implication for atherosclerosis.Biochem Pharmacol. 2003 Dec 1;66(11):2069-73. doi: 10.1016/s0006-2952(03)00559-8. Biochem Pharmacol. 2003. PMID: 14609731 Review.
-
[Changes in biological functions of high-density lipoprotein after abnormal modification].Sheng Li Xue Bao. 2017 Apr 25;69(2):225-234. Sheng Li Xue Bao. 2017. PMID: 28435982 Review. Chinese.
Cited by
-
Validation of the reconstituted high-density lipoprotein (rHDL) drug delivery platform using dilauryl fluorescein (DLF).Drug Deliv Transl Res. 2011 Apr;1(2):113-20. doi: 10.1007/s13346-010-0012-0. Drug Deliv Transl Res. 2011. PMID: 25788110
-
Targeted nanoparticles for pediatric leukemia therapy.Front Oncol. 2014 May 13;4:101. doi: 10.3389/fonc.2014.00101. eCollection 2014. Front Oncol. 2014. PMID: 24860784 Free PMC article. Review.
-
Apolipoprotein A-I and its mimetics for the treatment of atherosclerosis.Curr Opin Investig Drugs. 2010 Sep;11(9):989-96. Curr Opin Investig Drugs. 2010. PMID: 20730693 Free PMC article. Review.
-
Emerging HDL-based therapies for atherothrombotic vascular disease.Curr Treat Options Cardiovasc Med. 2007 Feb;9(1):60-70. doi: 10.1007/s11936-007-0052-z. Curr Treat Options Cardiovasc Med. 2007. PMID: 17378977
Publication types
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Medical
Miscellaneous